TargetMol

NU 7026

Product Code:
 
TAR-T2433
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2433-2mg2mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-5mg5mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-10mg10mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-25mg25mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-50mg50mg£351.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-100mg100mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2433-200mg200mg£605.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
CAS:
154447-35-5
Formula:
C17H15NO3
Molecular Weight:
281.311
Pathway:
Apoptosis; PI3K/Akt/mTOR signaling; DNA Damage/DNA Repair
Purity:
0.9996
SMILES:
O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1
Target:
Apoptosis; ATM/ATR; DNA-PK; PI3K

References

1. Veuger SJ, et al. Cancer Res, 2003, 63(18), 62008-62015. 2. Willmore E, et al. Blood, 2004, 103(12), 4659-4665. 3. Nutley BP, et al. Br J Cancer, 2005, 93(9), 12011-12018. 4. Amrein L, et al. J Pharmacol Exp Ther, 2007, 321(3), 848-855. 5. Williams ES, et al. Cancer Res, 2009, 69(5), 2100-2107.